Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAMPERO: Benralizumab in Uncontrolled Asthma (Medium-dose ICS-LABA)
NCT01947946Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Nov 2013
- Primary completion
- Jul 2014
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of benralizumab in asthma, sponsored by AstraZeneca. Started Nov 2013; status: terminated.
02
Drugs
benralizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01947946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01947946.